Refractory colorectal cancer patient derived MicroOrganoSpheres (MOS)TM enables correlation of targeted therapy combination response with clinical outcomes
Patient-derived MicroOrganoSpheres (MOS)TM enable precision clinical decision-making for multiple myeloma patients
Feasibility of establishing and drug screening patient-derived rectal organoid models from pretreatment rectal cancer biopsies
Micro-organospheres: An Automated Platform for Repid Drug Screening in Patient-Derived Breast Cancer Organoids
